Can CRS Achieve Its Upbeat FY26 Operating Income Guidance?
Carpenter Technology lifts its FY26 operating income outlook after a record third quarter, driven by aerospace and defense demand, pricing, and volume gains.
CRS - Carpenter Technology Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$502.80
DETAILS
HIGH:
$680.00
LOW:
$425.00
MEDIAN:
$459.00
CONSENSUS:
$502.80
DOWNSIDE:
14.92%
Stock News
Carpenter (CRS) Moves to Buy: Rationale Behind the Upgrade
Carpenter (CRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Carpenter Technology (CRS) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will Carpenter (CRS) Beat Estimates Again in Its Next Earnings Report?
Carpenter (CRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Carpenter Technology Announces Conference Call and Webcast
PHILADELPHIA, July 01, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) plans to host a conference call and webcast on Thursday, July 30, 2026 at 10:00 a.m. ET to discuss the results of operations for the fourth quarter of fiscal year 2026, ended June 30, 2026.
3 Reasons Why Growth Investors Shouldn't Overlook Carpenter (CRS)
Carpenter (CRS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Are You Looking for a Top Momentum Pick? Why Carpenter Technology (CRS) is a Great Choice
Does Carpenter Technology (CRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
DelphX Capital Markets Provides Corporate Update on Structured Income Program and CRS Commercialization
Advancing financing partner alignment for BTC Structured Income Program; in active discussions on a pilot transaction with a major U.S. insurer for Credit Rating Securities Toronto, Ontario and New York, New York--(Newsfile Corp. - June 23, 2026) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX" or the "Company") today provided a corporate update on two of its principal commercialization workstreams. BTC Structured Income Program - Financing Partner Alignment The Company is pleased to report that it has finalized and executed a definitive agreement with a leading global digital asset lender - recognized as one of the most active and established credit providers in the cryptocurrency sector - for the senior secured lending facility that forms the foundational layer of capital for the Company's BTC Structured Income Program (the "Program").
Carpenter Technology (CRS) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish
Shares in PPoolbeg Pharma PLC (AIM:POLB) rose 3% to 7.8p on Tuesday, taking their gain for the year to date to around 100%, after the drug developer secured a key European patent. The European Patent Office has agreed to grant a patent covering POLB 001, Poolbeg's experimental treatment for preventing cytokine release syndrome (CRS), a dangerous immune reaction triggered by some cancer immunotherapies.
Supporting the Mission: Catholic Relief Services Chooses Adstra as a Fundraising Partner
PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Adstra Nonprofit today announced a strategic partnership with Catholic Relief Services (CRS), one of the world's leading humanitarian organizations.
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi
Why X Money Could Be Bigger Than PayPal Ever Was
X Money isn't just a payments app. Elon Musk is building a financial super app that could reshape banking and investing.
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
OGN's TOFIDENCE gains FDA approval for life-threatening CRS and certain hospitalized COVID-19 patients, broadening its critical-care role.
Carpenter Technology Corporation (CRS) Hits Fresh High: Is There Still Room to Run?
Carpenter (CRS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon receives US FDA approval for expanded indications of TOFIDENCE, a biosimilar to ACTEMRA, in Cytokine Release Syndrome and Pediatric COVID-19.
Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Carpenter Technology (CRS) Is Up 8.03% in One Week: What You Should Know
Does Carpenter Technology (CRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Carpenter (CRS) Upgraded to Buy: Here's Why
Carpenter (CRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Price Targets
Carpenter Technology price target raised to $680 from $495 at Susquehanna
$680.00
(was $597.14)
Susquehanna
Carpenter Technology price target raised to $459 from $453 at KeyBanc
$459.00
(was $429.41)
Samuel McKinney
·
KeyBanc
Carpenter Technology price target raised to $425 from $400 at Wells Fargo
$425.00
(was $429.41)
Wells Fargo
Carpenter Technology price target raised to $500 from $495 at Deutsche Bank
$500.00
(was $420.53)
Deutsche Bank
Carpenter Technology price target raised to $495 from $470 at Susquehanna
$495.00
(was $406.53)
Susquehanna
Carpenter Technology price target raised to $450 from $375 at BTIG
$450.00
(was $406.53)
BTIG
Carpenter Technology price target raised to $453 from $380 at KeyBanc
$453.00
(was $431.21)
KeyBanc
Carpenter Technology price target raised to $375 from $365 at BTIG
$375.00
(was $310.39)
Andre Madrid
·
BTIG
Carpenter Technology price target raised to $365 from $305 at BTIG
$365.00
(was $316.71)
BTIG
Carpenter Technology price target raised to $425 from $375 at Deutsche Bank
$425.00
(was $300.27)
Deutsche Bank
Carpenter Technology price target raised to $230 from $210 at BTIG
$230.00
(was $193.06)
Andre Madrid
·
BTIG
Deutsche Bank Starts Carpenter Technology (CRS) at Buy
$144.00
(was $98.46)
Scott Deuschle
·
Deutsche Bank